Literature DB >> 33216735

SARS-CoV-2 B cell receptor signatures in at-risk populations.

Andrew I Flyak.   

Abstract

Many individuals possess B cells capable of recognizing epitopes on the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this issue of the JCI, Paschold and Simnica et al. interrogated the frequency of SARS-CoV-2-specific B cell receptor rearrangements in healthy subjects based on age and cancer status. The authors found that while SARS-CoV-2-specific antibody signatures can be identified in the repertoires of young, healthy individuals, such sequences are less frequent in elderly subjects or patients with cancer. Overall, this study sheds light on B cell repertoire restrictions that might lead to an unfavorable clinical course of coronavirus disease 2019 infection in at-risk populations.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33216735      PMCID: PMC7773361          DOI: 10.1172/JCI144685

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

Review 1.  Epidemiology and unique aspects of aging and infectious diseases.

Authors:  T T Yoshikawa
Journal:  Clin Infect Dis       Date:  2000-06-30       Impact factor: 9.079

Review 2.  The aging of the immune system.

Authors:  Daniela Weiskopf; Birgit Weinberger; Beatrix Grubeck-Loebenstein
Journal:  Transpl Int       Date:  2009-07-16       Impact factor: 3.782

Review 3.  Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.

Authors:  Wen Shi Lee; Adam K Wheatley; Stephen J Kent; Brandon J DeKosky
Journal:  Nat Microbiol       Date:  2020-09-09       Impact factor: 17.745

4.  The potential danger of suboptimal antibody responses in COVID-19.

Authors:  Akiko Iwasaki; Yexin Yang
Journal:  Nat Rev Immunol       Date:  2020-06       Impact factor: 53.106

5.  Comprehensive mapping of immune perturbations associated with severe COVID-19.

Authors:  Leticia Kuri-Cervantes; M Betina Pampena; Wenzhao Meng; Aaron M Rosenfeld; Caroline A G Ittner; Ariel R Weisman; Roseline S Agyekum; Divij Mathew; Amy E Baxter; Laura A Vella; Oliva Kuthuru; Sokratis A Apostolidis; Luanne Bershaw; Jeanette Dougherty; Allison R Greenplate; Ajinkya Pattekar; Justin Kim; Nicholas Han; Sigrid Gouma; Madison E Weirick; Claudia P Arevalo; Marcus J Bolton; Eileen C Goodwin; Elizabeth M Anderson; Scott E Hensley; Tiffanie K Jones; Nilam S Mangalmurti; Eline T Luning Prak; E John Wherry; Nuala J Meyer; Michael R Betts
Journal:  Sci Immunol       Date:  2020-07-15

6.  REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.

Authors:  Alina Baum; Dharani Ajithdoss; Richard Copin; Anbo Zhou; Kathryn Lanza; Nicole Negron; Min Ni; Yi Wei; Kusha Mohammadi; Bret Musser; Gurinder S Atwal; Adelekan Oyejide; Yenny Goez-Gazi; John Dutton; Elizabeth Clemmons; Hilary M Staples; Carmen Bartley; Benjamin Klaffke; Kendra Alfson; Michal Gazi; Olga Gonzalez; Edward Dick; Ricardo Carrion; Laurent Pessaint; Maciel Porto; Anthony Cook; Renita Brown; Vaneesha Ali; Jack Greenhouse; Tammy Taylor; Hanne Andersen; Mark G Lewis; Neil Stahl; Andrew J Murphy; George D Yancopoulos; Christos A Kyratsous
Journal:  Science       Date:  2020-10-09       Impact factor: 47.728

7.  Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response.

Authors:  Alexander Panda; Feng Qian; Subhasis Mohanty; David van Duin; Frances K Newman; Lin Zhang; Shu Chen; Virginia Towle; Robert B Belshe; Erol Fikrig; Heather G Allore; Ruth R Montgomery; Albert C Shaw
Journal:  J Immunol       Date:  2010-01-25       Impact factor: 5.422

8.  Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.

Authors:  Seth J Zost; Pavlo Gilchuk; Rita E Chen; James Brett Case; Joseph X Reidy; Andrew Trivette; Rachel S Nargi; Rachel E Sutton; Naveenchandra Suryadevara; Elaine C Chen; Elad Binshtein; Swathi Shrihari; Mario Ostrowski; Helen Y Chu; Jonathan E Didier; Keith W MacRenaris; Taylor Jones; Samuel Day; Luke Myers; F Eun-Hyung Lee; Doan C Nguyen; Ignacio Sanz; David R Martinez; Paul W Rothlauf; Louis-Marie Bloyet; Sean P J Whelan; Ralph S Baric; Larissa B Thackray; Michael S Diamond; Robert H Carnahan; James E Crowe
Journal:  Nat Med       Date:  2020-07-10       Impact factor: 87.241

9.  Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.

Authors:  Christoph Kreer; Matthias Zehner; Timm Weber; Meryem S Ercanoglu; Lutz Gieselmann; Cornelius Rohde; Sandro Halwe; Michael Korenkov; Philipp Schommers; Kanika Vanshylla; Veronica Di Cristanziano; Hanna Janicki; Reinhild Brinker; Artem Ashurov; Verena Krähling; Alexandra Kupke; Hadas Cohen-Dvashi; Manuel Koch; Jan Mathis Eckert; Simone Lederer; Nico Pfeifer; Timo Wolf; Maria J G T Vehreschild; Clemens Wendtner; Ron Diskin; Henning Gruell; Stephan Becker; Florian Klein
Journal:  Cell       Date:  2020-07-13       Impact factor: 41.582

10.  The age distribution of mortality from novel coronavirus disease (COVID-19) suggests no large difference of susceptibility by age.

Authors:  Ryosuke Omori; Ryota Matsuyama; Yukihiko Nakata
Journal:  Sci Rep       Date:  2020-10-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.